Nutex Health Inc. (NUTX) 株式分析

企業概要

Nutex Health Inc. operates as a healthcare services and operations entity within the United States, utilizing a diversified business model that spans three distinct segments: Hospital, Population Health Management (PHM), and Real Estate. The company's Hospital segment is specifically dedicated to the development and operation of a network comprising micro hospitals, specialty hospitals, and similar facilities, while the other segments focus on broader population health strategies and real estate assets. This enterprise functions within the Healthcare sector, specifically classified under the Medical Care Facilities industry, positioning it as a provider of essential medical infrastructure and operational services. The company demonstrates significant scale with a market capitalization of $727.70M and an annual revenue of $875.26M, supported by a workforce of 944 employees. These valuation and revenue figures indicate that Nutex Health holds a substantial position in the specialized healthcare market, reflecting its capacity to manage large-scale hospital networks and generate significant operational cash flows relative to its peer group in the medical care facilities industry.

財務健全性

The financial performance of Nutex Health Inc. is characterized by robust profitability metrics, with a Trailing Twelve Months (TTM) revenue of $875.26M, net income of $70.79M, and EBITDA of $413.16M. The substantial gap between the revenue figure and the net income reveals a highly efficient cost structure where operating expenses are tightly managed, allowing a profit margin of 8.1% to be realized from the top line. This efficiency is further highlighted by an EBITDA that is more than five times the net income, suggesting strong operational leverage before interest, taxes, depreciation, and amortization. The company generates free cash flow of $152.81M, which signifies strong financial flexibility to fund capital expenditures, service debt obligations, or pursue strategic acquisitions without relying on external financing. The company maintains a cash balance of $185.57M against total debt of $351.39M, resulting in a debt-to-equity ratio of 82.99, which indicates a highly leveraged balance sheet where equity capital is minimal relative to total debt obligations. Despite the leverage, the current ratio stands at 3.41, indicating a very conservative short-term liquidity position with current assets significantly exceeding current liabilities. Return on Equity is reported at an exceptionally high 58.9%, while Return on Assets is 31.2%, metrics that reveal management's effectiveness in generating substantial returns on the company's equity base and total asset deployment.

バリュエーション評価

Valuation multiples for Nutex Health Inc. present a mixed picture of current profitability expectations versus future growth potential. The Trailing P/E ratio is 9.82, while the Forward P/E is significantly lower at 5.06, implying that the market expects earnings to grow substantially in the future to justify the current stock price relative to projected performance. The price-to-book ratio is 2.21, indicating that the market values the company at a premium of 121% over its net book value, suggesting investors place a high value on the company's intangible assets or growth prospects beyond its tangible equity. Alternative valuation metrics provide further context, with a Price-to-Sales ratio of 0.83 and an EV/EBITDA of 2.36, which suggests the company is trading at a discount relative to its sales and earnings power compared to typical industry peers. Regarding trading range, the 52-week high is $193.07 and the low is $77.21, providing a clear benchmark for price volatility over the past year. The stock's beta is 2.02, which means the share price is expected to be twice as volatile as the broader market, amplifying both upside potential during bull markets and downside risk during market corrections.

Growth & Income

The growth profile of the company shows contraction in the current period, with revenue growth year-over-year at -41.1% and earnings growth at -86.2%. These negative growth rates indicate that earnings are shrinking at a much faster pace than revenue, suggesting that cost reductions or one-time charges are impacting the bottom line more severely than the top line in this specific reporting period. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all of its earnings back into the business for operations, debt reduction, or strategic growth initiatives rather than distributing cash to shareholders. This reinvestment strategy is typical for companies with high growth needs or those managing significant debt obligations to preserve liquidity. Overall, the company presents a profile of high financial efficiency and strong cash generation currently offset by significant year-over-year contraction in both revenue and earnings, with no income distribution to investors.